(NASDAQ: TCRX) Tscan Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.61%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.05%.
Tscan Therapeutics's earnings in 2026 is -$124,305,000.On average, 8 Wall Street analysts forecast TCRX's earnings for 2026 to be -$58,292,929, with the lowest TCRX earnings forecast at -$58,149,157, and the highest TCRX earnings forecast at -$57,639,421. On average, 8 Wall Street analysts forecast TCRX's earnings for 2027 to be -$64,390,160, with the lowest TCRX earnings forecast at -$73,009,933, and the highest TCRX earnings forecast at -$59,697,971.
In 2028, TCRX is forecast to generate -$56,992,448 in earnings, with the lowest earnings forecast at -$67,886,429 and the highest earnings forecast at -$50,091,401.